GADETA B V has a total of 13 patent applications. It decreased the IP activity by 83.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are CHANGCHUN SR BIOLOGICAL TECH CO LTD, WUHAN INST OF BIOLOGICAL PRODUCTS CO LTD and PARAVAX INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Australia | 2 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Peptides | |
#5 | Microorganisms | |
#6 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Kuball Jürgen Herbert Ernst | 8 |
#2 | Gründer Elsa-Cordula | 6 |
#3 | Kierkels Guido Joris Jan | 5 |
#4 | Sebestyen Zsolt | 5 |
#5 | Kuball Jurgen Herbert Ernst | 4 |
#6 | Grunder Elsa-Cordula | 2 |
#7 | Kuball Juergen Herbert Ernst | 1 |
Publication | Filing date | Title |
---|---|---|
EP3469362A1 | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
AU2013240658A1 | Combinatorial gamma 9 delta 2 T cell receptor chain exchange |